sb 202190 has been researched along with Disease Exacerbation in 1 studies
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ueda, Y | 1 |
| Wang, S | 1 |
| Dumont, N | 1 |
| Yi, JY | 1 |
| Koh, Y | 1 |
| Arteaga, CL | 1 |
1 other study available for sb 202190 and Disease Exacerbation
| Article | Year |
|---|---|
Overexpression of HER2 (erbB2) in human breast epithelial cells unmasks transforming growth factor beta-induced cell motility.
Topics: Actins; Activin Receptors, Type I; Adenoviridae; Antibodies, Monoclonal; Antibodies, Monoclonal, Hum | 2004 |